The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis (DAIAR)
The Effect of an Anti-inflammatory Diet on Disease Activity and Quality of Life in Patients With Rheumatoid Arthritis - Parallel Controlled Randomized Clinical Trial
Rheumatoid arthritis (RA) is an autoimmune disease that affects 0.5-1% of the population and in which his remission is not always achieved, affecting physical and mental well-being and quality of life (QL). As a complement to pharmacotherapy, dietary intervention should be evaluated as a treatment option.
The main objective of this parallel controlled randomized clinical trial is to check the effect of an anti-inflammatory dietary intervention, compared to a diet based on the principles of the Mediterranean diet (control), on disease activity (AD) and improving QL.
Patients will be instructed to follow an anti-inflammatory diet (DAI) or a control diet (DC) for 6 months. The AD and QL will be evaluated at the end of the intervention.
As there are no dietary guidelines for RA, this study aims to provide scientific evidence about the impact of diet therapy on reducing AD and improving QL.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The main objective of this trial is to check the effect of an DAI, compared to a DC, on reducing AD and improving QL.
As secondary objectives, it is intended to investigate the relationship of DAI with inflammatory markers and with the modulation of the composition / diversity of the intestinal microbiota, in comparison with a DC.
This study combines all dietary components with an anti-inflammatory effect, thus allowing the possibility of evaluating the full potential of dietary treatment in the disease, including intestinal microbiota modulation.
These results are intended to further contribute to clinical decision making and better evidence-based treatment.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Portimão, Portugal
- Hospital Particular do Algarve - HPA Saúde
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age over 18 years;
- Presence of active disease, (DAS28≥ 2.6), under adequate control and medication.
- Able to sign informed consent
Exclusion Criteria:
- Any type of psychological deficiency, dementia or eating disorder;
- Presence of food allergies and / or intolerances;
- Be vegetarian or use Phytotherapy or other supplements (namely, pre and probiotics);
- Use of antibiotics im the last 6 months;
- Have had previous nutritional monitoring or change in eating habits in the last 6 months.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Diet Control
Diet Control (DC): nutritional education and adherence monitoring.
DC will be based on the Portuguese "Nova Roda dos Alimentos" following the principles of the Mediterranean diet.
|
Diet following mediterranean principles, for 15 weeks
|
|
Experimental: Diet Anti-inflammatory
Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring.
The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.
|
Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689.
doi: 10.1016/j.clnu.2020.08.020.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in disease activity
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group in the changes in Disease Activity (using DAS28 score: greater than 2,6 implies active disease), from baseline to the end of follow-up
|
15 weeks
|
|
Changes in Quality of Life
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group in changes in Quality of Life (Health Assessment Questionnaire (HAQ): scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability), from baseline to the end of follow-up
|
15 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in C-Reactive Protein (CRP)
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group in changes in C-Reactive Protein (CRP) measured in mg/L, from baseline to the end of follow-up
|
15 weeks
|
|
Changes in Erythrocyte Sedimentation Rate (ESR)
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group in changes in Erythrocyte Sedimentation Rate (ESR) measured in mm/h, from baseline to the end of follow-up
|
15 weeks
|
|
Changes in Rheumatoid Factor (RF)
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group changes in Rheumatoid Factor (RF) measured in IU/mL, from baseline to the end of follow-up
|
15 weeks
|
|
Changes in Gut microbiota
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group in the change of gut microbiota from baseline to the end of follow-up. Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage. |
15 weeks
|
|
Changes in weight
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group changes in weight, measured in Kg, from baseline to the end of follow-up
|
15 weeks
|
|
Changes in Body Mass Index (BMI)
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group changes in BMI, calculated using weight and height, presented in kg/m2: underweight < 18,5; normoweight 18,6-24,9; overweight 25-29,9; obese >30, from baseline to the end of follow-up
|
15 weeks
|
|
Changes in waist circumference perimeter
Periodo de tiempo: 15 weeks
|
Difference between the intervention and control group changes in waist circumference perimeter, measured in cm, from baseline to the end of follow-up
|
15 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- DAIAR
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .